Company / Tangible Book Value per Share
Neurocrine Biosciences Tangible Book Value per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Tangible Book Value per Share
$32.73
FY2025
5-year range
$11.87 / $32.73
FY2021-FY2025
Trend
+25.0%
vs FY2024
Sector context
#12 of 209
Health Care
What the data says
Among 209 Health Care companies, Neurocrine Biosciences is in the top 6% for tangible book value per share. Tangible Book Value per Share has increased for 3 consecutive years, from $11.87 in FY2022 to $32.73 in FY2025.
Based on SEC 10-K filings.
32.73 in FY2025 with a 5-year CAGR of +21.8%. Top quartile in the Health Care sector.
Improved from $23.07 to $32.73 over the past 2 years.
Health Care sector context is included.
Tangible Book Value per Share over time
Growth rates
- 3-Year CAGR
- +40.2%
- 5-Year CAGR
- +21.8%
- 10-Year CAGR
- -
Sector benchmark
-72.7% below sector average
Key checks
Key Insights
- Neurocrine Biosciences's tangible book value per share has grown for 3 consecutive years.
- In FY2025, tangible book value per share increased 25.0% year-over-year.
- Ranks #12 out of 209 companies in the Health Care sector.
- Lowest tangible book value per share in the period was in FY2016.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Tangible Book Value per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $32.73 | +25.0% |
| FY2024 | $26.18 | +13.5% |
| FY2023 | $23.07 | +94.4% |
| FY2022 | $11.87 | -19.2% |
| FY2021 | $14.70 | +20.4% |
| FY2020 | $12.20 | +73.9% |
| FY2019 | $7.01 | +29.5% |
| FY2018 | $5.41 | +26.4% |
| FY2017 | $4.28 | +17.4% |
| FY2016 | $3.65 | -34.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026